COMPASS Pathways' new CEO Kabir Nath
In July, COMPASS Pathways’ share price rose 40% – far outpacing the market’s rebound.
Notable inflection points included the release of positive financial results, conclusion of the patent dispute, the US government’s expectation that COMP360 will be regulated within the next 24 months, and the appointment of a CEO with extensive expertise in drug commercialisation.
Kabir Nath was previously Senior Managing Director of Global Pharmaceuticals at Otsuka, and served as President and CEO of Otsuka’s North America Pharmaceutical Business. To discuss the company’s transition and his mandate going forward, Nath sat down with PSYCH.READ MORE